Skip to main content

Table 1

From: Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)

Updated March 16, 2015 Retrsopective Cohort (2007-2012)N=97, 11 sites Prospective Cohort (2011-2015)N=311, 39 sites
mOS, months 48 NR
Median follow-up, months 43.8 18.7
1,2,3 year survival rate, CP/PR 100%, 89%, 84% 100%, 85%, 79%
1,2,3 year survival rate, SD 89%, 69%, 61% 95%, 76%, n/d
ORR 20% (CR: 5%, PR: 15%) 16% (CR: 3%, PR: 13%)
CR+PR+SD 49% 55%
mOS no prioir TT/prior TT 48.9 (n=82)/15.3 (n=15) NR (n=266)/22.1 (n=45)